Consensus Personalis, Inc.

Equities

PSNL

US71535D1063

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.25 ^USD	-3.85%		+3.31%	-40.48%

Mar. 26	Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	CI
Feb. 29	Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating	MT

Evolution of the average Target Price on Personalis, Inc.

Price target over the last 5 years

History of analyst recommendation changes

817685864c5891fb21956d7401421.nBK5p65f_kDq2lYnCQ-HlAlQxiw_YV1cTV2-WwZzCYE.12btkOZsyzWir2R9PV7O1VE08kJdDG0QOjjuKWg7YO_SQ87fxjSnN5i9Hw~39da1ffa0cab724bc5085531411e8dde

Analyst Recommendations on Personalis, Inc.

Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating	Feb. 29	MT
Needham Cuts Price Target on Personalis to $2.30 From $7, Maintains Buy Rating	Nov. 08	MT
HC Wainwright Adjusts Price Target on Personalis to $7.50 From $10, Maintains Buy Rating	23-08-09	MT
Needham Trims Price Target on Personalis to $7 From $8, Maintains Buy Rating	23-05-04	MT
Morgan Stanley Adjusts Price Target on Personalis to $5 From $11, Maintains Equal-Weight Rating	23-02-27	MT
HC Wainwright Trims Price Target on Personalis to $10 From $13, Maintains Buy Rating	23-02-24	MT
Needham Upgrades Personalis to Buy From Hold, Says Encouraged by Cost Reductions, Price Target is $8	23-02-06	MT
HC Wainwright Adjusts Personalis' Price Target to $13 From $26, Keeps Buy Rating	22-11-03	MT
Citigroup Adjusts Price Target on Personalis to $6 From $8, Maintains Buy Rating	22-11-03	MT
Citigroup Lowers Personalis' Price Target to $8 From $14, Maintains Buy Rating	22-08-04	MT
HC Wainwright Adjusts Personalis' Price Target to $26 From $30, Reiterates Buy Rating	22-08-04	MT
Citigroup Adjusts Personalis' Price Target to $14 from $18, Keeps Buy Rating	22-05-05	MT
HC Wainwright Adjusts Personalis' Price Target to $30 From $38, Reiterates Buy Rating	22-05-05	MT
HC Wainwright Adjusts Personalis Price Target to $38 From $50, Maintains Buy Rating	22-02-25	MT
Citigroup Adjusts Personalis Price Target to $18 From $30, Maintains Buy Rating	22-02-25	MT
Oppenheimer Adjusts Personalis' Price Target to $24 From $30, Maintains Outperform Rating	22-02-25	MT
Morgan Stanley Adjusts Personalis Price Target to $14 From $25, Maintains Equalweight Rating	22-02-15	MT
Morgan Stanley Downgrades Personalis to Equalweight from Overweight, Adjusts Price Target to $25 from $32	21-11-08	MT
Needham Downgrades Personalis to Hold From Buy on VA Program Uncertainty, Cash Burn, Model Change; $28 PT Removed	21-11-03	MT
PERSONALIS : BTIG Adjusts Personalis' Price Target to $30 from $35, Keeps Buy Rating	21-09-21	MT
PERSONALIS : Needham & Co Adjusts Personalis PT to $28 From $33, Maintains Buy Rating	21-09-20	MT
PERSONALIS : Citigroup Adjusts Personalis' Price Target to $30 From $37, Maintains Buy Rating	21-08-05	MT
PERSONALIS : Truist Securities Adjusts Personalis PT to $29 From $37, Maintains Buy Rating	21-05-13	MT
PERSONALIS : Morgan Stanley Adjusts Personalis PT to $35 From $38, Maintains Overweight Rating	21-05-07	MT
PERSONALIS : Oppenheimer Upgrades Personalis to Outperform From Perform as Pharma Business Sets Up for High Growth, $28 PT	21-05-06	MT